Form 8-K - Current report:
SEC Accession No. 0001193125-24-220534
Filing Date
2024-09-17
Accepted
2024-09-17 16:10:30
Documents
13
Period of Report
2024-09-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d260865d8k.htm   iXBRL 8-K 25661
  Complete submission text file 0001193125-24-220534.txt   147630

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20240916.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20240916_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20240916_pre.xml EX-101.PRE 11259
15 EXTRACTED XBRL INSTANCE DOCUMENT d260865d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241304346
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)